<DOC>
	<DOCNO>NCT01541189</DOCNO>
	<brief_summary>To evaluate efficacy safety valsartan 160mg Chinese hypertensive patient .</brief_summary>
	<brief_title>Double-dose Valsartan Monotherapy Hypertension Treatment : Effectiveness Safety Evaluation Chinese Patients .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Naive primary hypertension patient primary hypertensive patient mono antihypertensive therapy : All treatmentnaive patient need 140mmHg≤MSSBP &lt; 180mmHg 90mmHg≤MSDBP &lt; 110mmHg visit 1 For patient mono antihypertensive therapy , MSSBP/MSDBP &lt; 160/100mmHg visit 1 ( begin screen period ) ; visit 2 ( begin theraputic period ) , MSSBP≥140 mmHg &lt; 180mmHg AND MSDBP≥90 mmHg &lt; 110mmHg Severe hypertension Malignant hypertension Secondary hypertension Renal dysfunction ( serum creatinine &gt; 2.0mg ( 176.8μmol/L ) visit 1 ) Hepatic disease History hypertensive encephalopathy cerebrovascular accident within 6 month History myocardial infarction , coronary revascularization within 6 month Type 1 diabetes mellitus patietns HbA1c &gt; 8 % visit 1 Women pregnancy lactation Potentially fertile female patient use effective contraceptive method Be allergy study drug . Other protocol define inclusion/exlusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hypertension</keyword>
	<keyword>valsartan</keyword>
</DOC>